[go: up one dir, main page]

BR9809368A - Composições sólidas adequadas para administração oral compreendendo l-carnitina ou fumarato de magnésio de alcanoil-l-carnitina. - Google Patents

Composições sólidas adequadas para administração oral compreendendo l-carnitina ou fumarato de magnésio de alcanoil-l-carnitina.

Info

Publication number
BR9809368A
BR9809368A BR9809368-1A BR9809368A BR9809368A BR 9809368 A BR9809368 A BR 9809368A BR 9809368 A BR9809368 A BR 9809368A BR 9809368 A BR9809368 A BR 9809368A
Authority
BR
Brazil
Prior art keywords
carnitine
magnesium
solid compositions
alkanoyl
fumarate
Prior art date
Application number
BR9809368-1A
Other languages
English (en)
Inventor
Mose Santaniello
Nazareno Scafetta
Maria Ornella Tinti
Original Assignee
Sigma Tau Ind Famaceutiche Riu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Famaceutiche Riu filed Critical Sigma Tau Ind Famaceutiche Riu
Publication of BR9809368A publication Critical patent/BR9809368A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: <B>''COMPOSIçõES SóLIDAS ADEQUADAS PARA ADMINISTRAçãO ORAL COMPREENDENDO L-CARNITINA OU FUMARATO DE MAGNéSIO DE ALCANOIL-L-CARNITINA''<D>. Sais estáveis e não-higroscópicos consistindo em L-carnitina ou fumarato de magnésio de alcanoil-L-carnitina são descritos, os quais são adequados para preparar composições sólidas úteis como suplementos de dieta/nutricionais para uso humano e como suplemento para forragem para propósitos veterinários.
BR9809368-1A 1997-04-30 1998-04-08 Composições sólidas adequadas para administração oral compreendendo l-carnitina ou fumarato de magnésio de alcanoil-l-carnitina. BR9809368A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97RM000254A IT1290600B1 (it) 1997-04-30 1997-04-30 Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato
PCT/IT1998/000079 WO1998049134A1 (en) 1997-04-30 1998-04-08 Solid compositions suitable for oral administration comprising l-carnitine or alkanoyl-l-carnitine magnesium fumarate

Publications (1)

Publication Number Publication Date
BR9809368A true BR9809368A (pt) 2000-07-04

Family

ID=11405029

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809368-1A BR9809368A (pt) 1997-04-30 1998-04-08 Composições sólidas adequadas para administração oral compreendendo l-carnitina ou fumarato de magnésio de alcanoil-l-carnitina.

Country Status (22)

Country Link
US (1) US6051608A (pt)
EP (1) EP0979224B1 (pt)
JP (1) JP2001524106A (pt)
KR (1) KR100556238B1 (pt)
CN (1) CN1137088C (pt)
AT (1) ATE220659T1 (pt)
AU (1) AU733008B2 (pt)
BR (1) BR9809368A (pt)
CA (1) CA2288287C (pt)
CZ (1) CZ290159B6 (pt)
DE (1) DE69806590T2 (pt)
DK (1) DK0979224T3 (pt)
ES (1) ES2179485T3 (pt)
HK (1) HK1025559A1 (pt)
HU (1) HUP0002198A3 (pt)
IL (2) IL132275A0 (pt)
IT (1) IT1290600B1 (pt)
NZ (1) NZ500536A (pt)
PL (1) PL189602B1 (pt)
PT (1) PT979224E (pt)
SK (1) SK283818B6 (pt)
WO (1) WO1998049134A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352485A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
IT1305308B1 (it) * 1999-03-26 2001-05-04 Biosint S P A Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
US6429230B1 (en) * 2000-01-19 2002-08-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treating chronic uremic patients undergoing periodical dialysis
US6335369B1 (en) * 2000-01-19 2002-01-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treating chronic uremic patients undergoing periodical dialysis
US6914076B2 (en) * 2000-01-19 2005-07-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treating chronic uremic patients undergoing periodical dialysis
KR20010084849A (ko) * 2000-02-29 2001-09-06 손 경 식 Ｌ-카르니틴을 이용한 기능성 우유 및 그 제조 방법
ATE295690T1 (de) * 2000-08-29 2005-06-15 Lonza Ag Verfahren zur herstellung einer granulierbaren mischung und carnitin-magnesium-hydroxycitrat
DE10133200A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Carnitin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
ITRM20010695A1 (it) * 2001-11-26 2003-05-26 Sigma Tau Ind Farmaceuti Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del
US20030235646A1 (en) * 2002-03-15 2003-12-25 Lonza Inc. Method for improving quality of meat by supplementing pig diets and concentrates used therefor
JP4539096B2 (ja) * 2004-01-16 2010-09-08 日油株式会社 油性成分被覆ｌ−カルニチン塩粉末およびその用途
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
JP2006111550A (ja) * 2004-10-13 2006-04-27 Nisshin Pharma Inc カルニチン含有製品
CN100518537C (zh) * 2006-01-13 2009-07-29 天津天隆农业科技有限公司 一种含有二十八烷醇和l-肉碱的水产饲料及其生产方法
CN101209975B (zh) * 2006-12-29 2010-12-01 沈阳科硕营养科技有限公司 左旋肉碱富马酸钙及其制备方法与用途
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153640A (en) * 1967-04-10 1969-05-29 Soc D Etudes Prod Chimique A Carnitin Salt
FR2529545B1 (fr) * 1982-07-02 1985-05-31 Sanofi Sa Nouveaux sels de carnitine ainsi que leur procede de preparation
DE3463261D1 (en) * 1983-12-28 1987-05-27 Sigma Tau Ind Farmaceuti Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
CA2018137C (en) * 1989-06-14 2000-01-11 Thomas Scholl L-carnitine magnesium citrate
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
IT1261688B (it) * 1993-05-28 1996-05-29 Avantgarde Spa Uso di esteri sull'ossidrile della l-carnitina per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.

Also Published As

Publication number Publication date
ES2179485T3 (es) 2003-01-16
AU7077698A (en) 1998-11-24
HUP0002198A2 (hu) 2000-11-28
KR20010020320A (ko) 2001-03-15
ATE220659T1 (de) 2002-08-15
IT1290600B1 (it) 1998-12-10
DE69806590D1 (de) 2002-08-22
CZ290159B6 (cs) 2002-06-12
SK146299A3 (en) 2000-09-12
US6051608A (en) 2000-04-18
HUP0002198A3 (en) 2001-10-29
NZ500536A (en) 2001-04-27
CN1253544A (zh) 2000-05-17
HK1025559A1 (en) 2000-11-17
ITRM970254A1 (it) 1998-10-30
PL336530A1 (en) 2000-07-03
JP2001524106A (ja) 2001-11-27
CN1137088C (zh) 2004-02-04
CZ381399A3 (cs) 2000-02-16
IL132275A0 (en) 2001-03-19
PT979224E (pt) 2002-12-31
ITRM970254A0 (it) 1997-04-30
AU733008B2 (en) 2001-05-03
SK283818B6 (sk) 2004-02-03
IL132275A (en) 2006-08-01
WO1998049134A1 (en) 1998-11-05
KR100556238B1 (ko) 2006-03-03
CA2288287A1 (en) 1998-11-05
PL189602B1 (pl) 2005-08-31
CA2288287C (en) 2008-06-10
DK0979224T3 (da) 2002-09-02
DE69806590T2 (de) 2003-01-30
EP0979224B1 (en) 2002-07-17
EP0979224A1 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
BR9809368A (pt) Composições sólidas adequadas para administração oral compreendendo l-carnitina ou fumarato de magnésio de alcanoil-l-carnitina.
CY1107349T1 (el) Αλφα-κετογλουταρικα ενεργα συστατικα και σκευασματα που τα περιεχουν
BR9808494A (pt) Composições sólidas adequadas para administração oral as quais compreendem um citrato de alcanoil-l-carnitina magnésio
BR9808489A (pt) Composições sólidas adequadas para administração oral as quais compreendem l-carnitina e tartrato de alcanoil-l-carnitino magnésio
BR9808908A (pt) Composições sólidas adequadas para administração oral que compreendem l-carnitina ou tartarato de alcanoil-l-carnitina colina
BR9808461A (pt) Método para composições sólidas adequadas para administração oral compreendendo sais não higroscópicos de l-carnitina e alcanoil-l-carnitina com ácido 2-aminoetassulfÈnico.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/205, A61K 31/197, C07C 57/15, C07C 229/22, C07C 217/04, C07C 215/08, C07C 215/40, A23L 1/305, A23K 1/16, A61K 9/20, A61P 9/04, A61P 9/06, A61P 9/10, A61P 21/02, A61P 21/04

Ipc: A61K 31/205 (2008.04), A61K 31/197 (2008.04), C07C

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time
B15K Others concerning applications: alteration of classification

Ipc: C07C 229/22 (2006.01), A23K 20/105 (2016.0